Adults 18 to 70, any sex, with Hoarding Disorder or Hoarding. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Patients Who Met and Exceeded Response Criteria of the Saving Inventory-Revised (SI-R)Primary· Change from baseline (pre-treatment) to week 18 (post-treatment) the Immediate Treatment Arm/Group and change from baseline (pre-treatment at 18 weeks) to 36 weeks (post-treatment) for the Delayed Treatment Arm/Group
The SI-R is a 23-item questionnaire with 3 sub-scales for difficulty discarding, excessive clutter, and compulsive acquisition.
The total score ranges from 0 to 92. The greater the score, the more severe the hoarding symptoms. Total score higher than 41 shows significant difficulty with clutter.
For the acquisition subscale, items 2 (reverse score), 9, 11, 14, 16, 18 and 21 are summed together. The subscale ranges from 0 to 28 and score greater than 13 indicates difficulty with excessive acquisition.
For the difficulty discarding subscale, items 4(reverse score), 6, 7, 13, 17, 19, 23 are su
Group
Value
95% CI
Immediate Treatment
9
Delayed Treatment
13
Sponsor's own description
The proposed study aims to investigate the efficacy of adding in-home decluttering practice to Buried in Treasures Workshop (BIT) facilitated group treatment for hoarding disorder.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02843308.